CD19 and glycogen storage disease VI: CAR T cells designed to target CD19 have demonstrated remarkable safety and efficacy in treating acute lymphoblastic leukemia (ALL), leading to complete remission with the absence of minimal residual disease in 67 to 85% of patients given CD19 CAR therapy (9–15).